Results 41 to 50 of about 92,044 (339)

lncRNA DARS-AS1 Modulates TSPAN1-Mediated ITGA2 Hypomethylation by Interaction with miR-194-5p Thus Promoting Ovarian Cancer Progression

Stem Cells International, 2022
Objective. Ovarian cancer (OC) is usually called the “silent killer” due to its asymptomatic characteristics until advanced stages, thus being a significant threat to female health worldwide.
Jun Li, Haoyu Gao, Beibei Chen, Li Li, Qianqing Wang, Zhihui Gao   +5 more
doaj   +1 more source

Multimodal Magnetic Resonance and Near-Infrared-Fluorescent Imaging of Intraperitoneal Ovarian Cancer Using a Dual-Mode-Dual-Gadolinium Liposomal Contrast Agent. [PDF]

, 2016
The degree of tumor removal at surgery is a major factor in predicting outcome for ovarian cancer. A single multimodality agent that can be used with magnetic resonance (MR) for staging and pre-surgical planning, and with optical imaging to aid surgical ...
Annapragada, A, Anvari, B, Bankson, J, Bhavane, R, Kundra, V, Ravoori, MK, Singh, S, Sood, AK   +7 more
core   +2 more sources

Tumor and germline testing with next generation sequencing in epithelial ovarian cancer: a prospective paired comparison using an 18‐gene panel

Molecular Oncology, EarlyView.
Genetic testing in epithelial ovarian cancer includes both germline and tumor‐testing. This approach often duplicates resources. The current prospective study assessed the feasibility of tumor‐first multigene testing by comparing tumor tissue with germline testing of peripheral blood using an 18‐gene NGS panel in 106 patients.
Elisabeth Spenard, Cristina Mitric, Melanie Care, Tracy L. Stockley, Raymond H. Kim, Jeanna McCuaig, Blaise Clarke, Laura Ranich, Clare Sheen, Sarah E. Ferguson, Liat Hogen, Taymaa May, Marcus Q. Bernardini   +12 more
wiley   +1 more source

Validation of a Multivariate Serum Profile for Epithelial Ovarian Cancer Using a Prospective Multi-Site Collection [PDF]

, 2010
In previous studies we described the use of a retrospective collection of ovarian cancer and benign disease samples, in combination with a large set of multiplexed immunoassays and a multivariate pattern recognition algorithm, to develop an 11-biomarker ...
Beth Y. Karlan, Brian C. Mansfield, Brigitte E. Miller, Eva Chalas, Glenn E. Bigsby, Greg P. Bertenshaw, James F. Barter, James P. Mapes, James W. Orr, Jinghua Zhao, Katharine J. Bergstrom, Laurie L. Stephen, Lynda D. Roman, Michael E. McCollum, Partha Seshaiah, Paul A. DiSilvestro, Ping F. Yip, Robert W. Holloway, Ronald D. Alvarez, Suraj Amonkar, Tzong-Hao Chen   +20 more
core   +1 more source

Infrared laser sampling of low volumes combined with shotgun lipidomics reveals lipid markers in palatine tonsil carcinoma

Molecular Oncology, EarlyView.
Nanosecond infrared laser (NIRL) low‐volume sampling combined with shotgun lipidomics uncovers distinct lipidome alterations in oropharyngeal squamous cell carcinoma (OPSCC) of the palatine tonsil. Several lipid species consistently differentiate tumor from healthy tissue, highlighting their potential as diagnostic markers.
Leonard Kerkhoff, Manuela Moritz, Dennis Eggert, Anna Worthmann, Joerg Heeren, Henrike Zech, Till S. Clauditz, Waldemar Wilczak, Hartmut Schlüter, Christian S. Betz, Arne Böttcher, Jan Hahn   +11 more
wiley   +1 more source

Goal-Directed Intraoperative Fluid Therapy Benefits Patients Undergoing Major Gynecologic Oncology Surgery: A Controlled Before-and-After Study

Frontiers in Oncology, 2022
BackgroundFluid management during major gynecologic oncology surgeries faces great challenges due to the distinctive characteristics of patients with gynecologic malignancies as well as features of the surgical procedure.
Jiawen Yu, Lu Che, Afang Zhu, Li Xu, Yuguang Huang   +4 more
doaj   +1 more source

Efficacy and toxicity of bevacizumab in recurrent ovarian disease: an update meta-analysis on phase III trials [PDF]

, 2015
Background: To analyze the efficacy and toxicity of bevacizumab on survival outcomes in recurrent ovarian cancer. Results: Bevacizumab was associated with significant improvement of PFS and OS compared with standard treatment with HRs of 0.53 (95% CI 0.
BENEDETTI PANICI, PIERLUIGI, DE FELICE, FRANCESCA, DI DONATO, VIOLANTE, GASPARRI, MARIALUISA, Marchetti, C, MUSELLA, ANGELA, Musio, D, MUZII, LUDOVICO, PALAIA, INNOCENZA, TOMBOLINI, Vincenzo   +9 more
core   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source

Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA) [PDF]

, 2009
Background: In this study we aimed to evaluate the role of a SNP in intron 1 of the ERCC4 gene (rs744154), previously reported to be associated with a reduced risk of breast cancer in the general population, as a breast cancer risk modifier in BRCA1 and ...
A Allavena, A Antoniou, A B Spurdle, A C Antoniou, A E Toland, A K Godwin, A Meindl, A Miron, A Osorio, A Osorio, A van den Ouweland, A Viel, A-C Spiess, A-M Gerdes, AC Antoniou, AC Antoniou, B Arver, B Fiebig, B Kaufman, B Malmer, B Versmold, C Casella, C Cassini, C Engel, C F Singer, C I Szabo, C Kiyohara, C Luccarini, C T Oliver, D F Easton, D Ford, D Frost, D G Cruger, D G Evans, D Goldgar, D Gschwantler-Kaulich, D Muller, D Niederacher, D Schaefer, D Stoppa-Lyonnet, D Yannoukakos, DF Easton, DF Easton, E Dagan, E Friedman, E M John, E N Imyanitov, EB Gómez García, F B L Hogervorst, F Douglas, F J Couch, F Lalloo, F Lejbkowicz, F Révillion, G C Rodriguez, G Chenevix-Trench, G Chenevix-Trench, G Pfeiler, G Pichert, G Pita, G Rennert, H Deißler, H Jernström, H Nevanlinna, H Ozcelik, H T Lynch, I L Andrulis, J Basil, J Beesley, J Benítez, J Brunet, J Cook, J F Boggess, J L Hopper, J Simard, J T Wijnen, J-P Fricker, J-P Peyrat, K Claes, K Kosarin, K L Nathanson, K Lange, K Offit, K Wakeley, L Barjhoux, L Foretova, L McGuffog, L Olivier-Faivre, L Tizzoni, LE Mechanic, M A Caligo, M B Terry, M Barile, M Cook, M Daly, M de la Hoya, M Garcia-Closas, M H Greene, M Montagna, M Piedmonte, M S Askmalm, M Thomassen, M Zikan, MM Gaudet, N Arnold, N Ditsch, N Lindor, N Weerasooriya, O Barnett-Griness, O M Sinilnikova, O T Johannsson, P E Schwartz, P J Morrison, P Mai, P Peterlongo, P Radice, R Eeles, R Gershoni-Baruch, R K Schmutzler, R L Milne, R Varon-Mateeva, RL Milne, RL Milne, S Buys, S Chen, S Cohen, S Giraud, S Healey, S Hodgson, S Hooker, S L Neuhausen, S M Domchek, S Manoukian, S Peock, S V Blank, S Verhoef, T Caldes, T Heikkinen, T Kirchhoff, T Kontorovich, T Ramón y Cajal, Thomas v O Hansen, TR Smith, U G Froster, U Hamann, V Moncoutier, V Moreno, X Chen, X Wang, Y C Ding, Y Laitman, Y Yassin   +151 more
core   +4 more sources

Phenotypic and genotypic characterization of single circulating tumor cells in the follow‐up of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon, Rui P. L. Neves, Nikolas H. Stoecklein, Sven‐Thorsten Liffers, Jens Siveke, Jan D. Kuhlmann, Pauline Wimberger, Paul Buderath, Rainer Kimmig, Sabine Kasimir‐Bauer   +9 more
wiley   +1 more source